IL28B genetic variations are associated with treatment response of patients with chronic hepatitis C in a Chinese Han population

Publisher： John Wiley & Sons Inc

E-ISSN： 1751-2980|16|2|90-97

ISSN： 1751-2972

Source： Journal of Digestive Diseases, Vol.16, Iss.2, 2015-02, pp. : 90-97

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Is there clinical utility to IL28B genotype testing in the treatment of chronic hepatitis C virus infection?

By Liapakis AnnMarie   Jesudian Arun B  

Pharmacogenomics, Vol. 13, Iss. 12, 2012-09 ,pp. : 1317-1319

Future Medicine

Access to resources Recommend Favorite

Single and combined IL28B, ITPA and SLC28A3 host genetic markers modulating response to anti-hepatitis C therapy

By Lötsch Jörn   Hofmann Wolf Peter   Schlecker Christina   Zeuzem Stefan   Geisslinger Gerd   Ultsch Alfred   Doehring Alexandra  

Pharmacogenomics, Vol. 12, Iss. 12, 2011-12 ,pp. : 1729-1740

Future Medicine

Access to resources Recommend Favorite

Predictors of response to chronic hepatitis C treatment

By Ridruejo Ezequiel  

Future Virology, Vol. 7, Iss. 11, 2012-11 ,pp. : 1089-1101

Future Medicine

Access to resources Recommend Favorite

Treatment of chronic hepatitis B and C in children

By Indolfi Giuseppe   Nesi Alessandro   Resti Massimo  

Future Virology, Vol. 7, Iss. 10, 2012-10 ,pp. : 955-972

Future Medicine

Access to resources Recommend Favorite

Population pharmacokinetics of peginterferon alfa-2b in pediatric patients with chronic hepatitis C

By Xu C.   Gupta S.   Krishna G.   Cutler D.   Wirth S.   Galoppo C.   Ciocca M.   Kolz K.   Noviello S.   Sniukiene V.  

European Journal of Clinical Pharmacology, Vol. 69, Iss. 12, 2013-12 ,pp. : 2045-2054

Springer Publishing Company

Access to resources Recommend Favorite